Prognostic scores for cirrhotic patients admitted to an intensive care unit: which consequences for liver

Arnaud Galbois1, Vincent Das, Nicolas Carbonell

  • 1AP-HP, Hôpital Saint-Antoine, Service de Réanimation Médicale, 75012 Paris, France; UPMC, Université Paris 06, Sorbonne Universités, 75006 Paris, France; INSERM, UMR_S 938, CdR Saint-Antoine, 75012 Paris, France.

Insights

Critically ill cirrhotic patients in intensive care units (ICUs) have increased mortality. The CLIF-SOFA score, tailored for cirrhotic patients, shows promise in predicting outcomes and guiding liver transplantation (LT) decisions.

Area of Science:

  • Hepatology
  • Critical Care Medicine
  • Prognostic Score Development

Background:

  • Cirrhotic patients admitted to the ICU face elevated mortality risks regardless of the admission cause.
  • Existing prognostic scores (liver-specific, general, organ failure) have limitations in predicting outcomes for critically ill cirrhotic patients.
  • Organ failure scores are generally superior predictors of outcome in this population.

Purpose of the Study:

  • To evaluate the utility of prognostic scores in critically ill cirrhotic patients.
  • To address the dilemma of organ allocation for cirrhotic patients with acute organ failure.
  • To introduce and validate the CLIF-SOFA score for improved mortality prediction and liver transplantation (LT) candidacy assessment in ICUs.

Main Methods:

  • Review and comparison of various prognostic scores: CTP, MELD, SAPS II, APACHE, OSF, SOFA.
  • Analysis of the influence of acute disease and underlying cirrhosis on score components.
  • Introduction of the CLIF-SOFA score by the EASL-CLIF Consortium, redefining SOFA with cirrhotic-specific cut-offs.

Main Results:

  • Organ failure scores, particularly SOFA, are identified as key predictors of outcome in cirrhotic ICU patients.
  • The standard SOFA score predicts a higher risk of death for patients awaiting LT but not necessarily worse post-LT outcomes.
  • The CLIF-SOFA score is proposed as an ideal ICU score due to its focus on organ failures with specific cut-off values for cirrhotic patients.

Conclusions:

  • Accurate identification of cirrhotic patients who will benefit most from LT is crucial.
  • The CLIF-SOFA score offers a promising approach for prognostication and LT selection in critically ill cirrhotic patients.
  • Further validation of the CLIF-SOFA score in ICU settings is necessary to confirm its utility in guiding LT decisions.

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...